Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Oncology in Practice
  3. Palliative and Supportive care
  4. Multikinase Inhibitor-Related Skin Toxicity

Acknowledgements

Bayer Healthcare

The European Society for Medical Oncology (ESMO) wishes to thank Bayer HealthCare Pharmaceuticals for supporting this section on Dermatological Side Effects of Multikinase Inhibitors.

Medical writing support was provided by Mark English, PhD and Nadina Grosios, PhD, MPH of COR2Ed GmbH.

Table of Contents

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.